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ABSTRACT: Although serine proteases are important
mediators of Mycobacterium tuberculosis (Mtb) virulence,
there are currently no tools to selectively block or visualize
members of this family of enzymes. Selective reporter
substrates or activity-based probes (ABPs) could provide a
means to monitor infection and response to therapy using
imaging methods. Here, we use a combination of substrate
selectivity profiling and focused screening to identify
optimized reporter substrates and ABPs for the Mtb
“Hydrolase important for pathogenesis 1” (Hip1) serine
protease. Hip1 is a cell-envelope-associated enzyme with
minimal homology to host proteases, making it an ideal target for probe development. We identified substituted 7-amino-4-
chloro-3-(2-bromoethoxy)isocoumarins as irreversible inhibitor scaffolds. Furthermore, we used specificity data to generate
selective reporter substrates and to further optimize a selective chloroisocoumarin inhibitor. These new reagents are potentially
useful in delineating the roles of Hip1 during pathogenesis or as diagnostic imaging tools for specifically monitoring Mtb
infections.
KEYWORDS: Mycobacterium tuberculosis, hydrolase important for pathogenesis 1 (Hip1), protease, activity-based probe,
fluorogenic substrate, substrate profiling
Standard pharmacological control of tuberculosis relies oncombination treatment using four drugs over a period of
several months.1 Although the emergence of multidrug and
extensively drug-resistant strains of Mycobacterium tuberculosis
(Mtb) highlights the need for novel antituberculosis agents,1,2
the lack of diagnostic methods to accurately and rapidly
monitor the drug-responsiveness of a patient imposes further
challenges for controlling infections in the clinic.3 The
development of targeted imaging agents that can directly
bind to or be activated by enzymes expressed only by Mtb
would be valuable for visualizing infection as well as monitoring
the response to therapy.
Visualizing the activity of individual proteases with chemical
probes has been established as a viable strategy for noninvasive
in vivo imaging of conditions such as cancer4 and
inflammation.5 Suitable chemical probes for these applications
include activity-based probes (ABPs, i.e., irreversible inhibitors
of a protease with a reporter tag6) as well as protease-activated
reporters such as quenched fluorescent substrates.7 A recent
chemoproteomic study revealed that Mtb expresses more than
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70 predicted serine hydrolases (including 6 annotated serine
proteases and 27 hypothetical hydrolases of unknown
function)8 that have the potential to be useful as imaging or
drug targets. The prioritization of a suitable target for the
design of new chemical probes for Mtb is based on a number of
basic criteria. These include a lack of homology to host
enzymes, expression during relevant stages of infection,
potential biological accessibility to the probes, and finally ease
of expression and purification to facilitate screening and
optimization of lead molecules. Mtb hydrolase important for
Table 1. Catalytic Efficiencies of Fluorogenic Substrates for M. tuberculosis Hip1 and Human Neutrophil Elastasea
a*No cleavage observed under 100 μM. n.d. = not determined.
Figure 1. Positional scanning-synthetic combinatorial libraries (PS-SCL)11 were used to profile the substrate specificity of Hip1. Cleavage of the
following sublibraries by Hip1 was measured in a fluorogenic substrate assay: (A) Ac-X-X-X-P1-ACC, (B) Ac-X-X-P2-X-ACC, (C) Ac-X-P3-X-X-
ACC, and (D) Ac-P4-X-X-X-ACC, where X represents a mixture of all natural amino acids (excluding Cys) and norleucine, whereas single amino
acids in the indicated P1−P4 positions are fixed, Ac = Acetyl. (E) Multiplex substrate profiling by mass spectrometry (MSP-MS)12 employing a set of
228 defined 14-mer peptides to monitor cleavage by Hip1 in an MS/MS-based readout. The iceLogo plot illustrates the P4 to P4′ specificity of Hip1.
Amino acids that are most frequently found at each position are shown above the horizontal line while amino acids least frequently observed are
below. Lowercase “n” is norleucine and amino acid in black text have p value < 0.05.
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pathogenesis 1 (Hip1, previously known as carboxylesterase A,
Rv2224c, MT2282)9 is a cell-envelope-associated serine
protease whose proteolytic activity is required for the
immunomodulation of host inflammatory responses.9e Its
established role in mycobacterial virulence makes it a potential
drug target.9e Furthermore, it shows only weak homology with
other host-derived serine proteases and it can be expressed
recombinantly in a proteolytically active form, therefore
fullfilling all of the criteria for an optimal target for chemical
probe design.
Hip1 was originally thought to be a carboxylesterase because
it was unable to cleave commonly used trypsin-like protease
substrates in vitro.9a However, a transposon mutant Hip1-KO
strain was found to be deficient in proteolytic processing of the
mycobacterial heat-shock protein GroEL2.9b This Hip1-KO
strain elicited increased proinflammatory responses from both
macrophages and neutrophils, indicating that the Hip1 catalytic
activity is involved in a down-regulation of the host immune
response.9c,d A later study revealed that Hip1 is indeed a serine
protease that can cleave GroEL2 both in vitro and in vivo,
resulting in the extracellular release of processed monomeric
GroEL2 as a mediator of Hip1-dependent immunomodulatory
activities.9e Although these studies demonstrated the physio-
logical relevance of Hip1-dependent proteolysis using genetic
methods, there are currently no chemical tools that can be used
to selectively inhibit or visualize Hip1 activity in live bacteria.
In this study, we demonstrate a strategy to develop chemical
probes (irreversible inhibitors, ABPs, and selective substrate
probes) for Mtb Hip1 activity by combining focused compound
library screening with multiple types of substrate selectivity
profiling. We identified key substrate determinants that are
important for recognition and turnover by Hip1 as well as a
chloroisocoumarin scaffold that irreversibly inhibits Hip1.
Combining the information from the specificity screen with
the lead compound scaffold resulted in both selective
fluorescent reporter substrates and a new class of covalent
inhibitors and active-site probes for Hip1. These reagents may
serve as leads for the development of clinically relevant drugs
and targeted imaging probes for visualizing Mtb infections.
Furthermore, the general approach and methodology presented
in this study should be applicable to designing probes for
virtually any serine protease of interest.
■ RESULTS AND DISCUSSION
M. tuberculosis Hip1 was produced as described previously,8 and
our initial studies revealed that it cleaved fluorogenic substrate
WKLL-ACC with a kcat/KM value of 1.9 × 10
3 M−1 s−1 (Table
1). This substrate was designed to be cleaved by another cell
envelope-associated Mtb protease, MarP,10 and was unlikely to
be optimal for Hip1. However, cleavage of the substrate
confirmed that the recombinant enzyme had proteolytic activity
and allowed us to determine optimal assay conditions for in-
depth substrate specificity studies. We initially used positional
scanning-synthetic combinatorial libraries (PS-SCL)11 and
multiplex substrate profiling by mass spectrometry (MSP-
MS)12 methods to survey the substrate specificity preferences
of recombinant Hip1 (Figure 1). The PS-SCL library method
allows a direct measure of the cleavage site specificity at the
P1−P4 positions, and the MSP-MS method uses mass
spectrometry to read out specific cleavages on 14-mer peptides
and provides data for specificity-driving residues on both sides
of the scissile amide bond. Our results using the PS-SCL
libraries showed that, overall, Hip1 has the most pronounced
selectivity at the P2 position, showing a strong preference for
lysine at this site (Figure 1B). We also observed some degree of
selectivity for aliphatic residues in the P1 position along with
selectivity for P1 glutamine or leucine (Figure 1A). At the P3
position, we observed specificity for aromatics and, to a lesser
degree, aliphatic residues (Figure 1C). Hip1 showed overall
minimal specificity at the P4 position with only a slight dislike
of negatively charged residues such as aspartic and glutamic
acids (Figure 1D). Importantly, the MSP-MS method produced
a specificity profile that agreed well with the PS-SCL data
(Figure 1E, Supporting Information Figure 1 A,B). In
particular, the preference for a P2 lysine was again the most
prominent specificity signature, and aliphatic P1 and aromatic
P3 specificities were also confirmed. Interestingly, glutamine
was neither preferred nor disfavored at the P1 position,
suggesting potential differences in the way the substrates are
presented in the active site for the two different methods. For
the prime sites, the MSP-MS analysis indicated a preference for
Gly, Phe, Arg, and Ser in the P1′ position and a variety of
hydrophobic aliphatic and aromatic residues on the P2′−P4′
sides, although none of these were particularly pronounced.
The only known proteolytic substrate of Hip1, GroEL2, is a
chaperone-like protein that has been reported to be cleaved at
two sites in its N-terminal region (AKT-IAYDEEARR-
GLERGLN, where the dashes indicate the cleavage sites).8
The first site features a lysine in the P2 position, in agreement
with the substrate preference we observed by MSP-MS and PS-
SCL. The second cleavage appears to have many suboptimal
amino acids in the P4−P4′ positions with the exception of
glycine in the P1′ position. Therefore, it is possible that Hip1
cleaves the first site at a faster rate compared to the second site.
Regardless, our Hip1 specificity data is consistent with
processing events occurring in a physiological substrate.
While this specificity information is valuable for the design of
probes, it may be difficult to use these in vitro data to identify
native substrates of Hip1 as its substrate specificity may differ
for actual protein substrates in vivo.
With the exception of norleucine, the PS-SCL and MSP-MS
assays utilize natural amino acids for substrate specificity
analysis. This provides a starting point for designing selective
substrates and for identifying putative cleavage sites on native
proteins. In order to increase the specificity of substrates, it is
possible to use non-natural amino acids. One method, referred
to as the hybrid combinatorial substrate library (HyCoSuL),
has been used to identify highly selective substrates for several
important protease targets including caspases,13 human
neutrophil elastase (HNE),14 and human neutrophil serine
protease 4.15 Therefore, we performed HyCoSuL profiling
using fluorogenic substrates containing a fixed P1 alanine and
102 non-natural and D-amino acids in the P2−P4 positions
(Supporting Information Figure 2). These results again
confirmed the high degree of substrate specificity of Hip1 for
a P2 lysine with a preference for this natural residue over all
other non-natural analogs including lysine analogs such as L-
ornithine, L-homoLys, and D-Lys (Supporting Information
Figure 2A). In further agreement with the PS-SCL and MSP-
MS results, we found that a number of non-natural aromatic
amino acids were accepted in the P3 position with the most
effective cleavage observed for L-4-chloro-phenylalanine
(4ClPhe). In the P4 position, L-indanylglycine (Igl) and L-
(benzyl)cysteine showed a 3- to 4-fold higher cleavage than for
any of the natural amino acids, suggesting that this position
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could be used to increase the specificity and turnover rates of
selective Hip1 substrates.
Using a combination of all of the profiling data, we designed
an optimized Hip1 substrate containing the L-amino acid
sequence acetyl-Igl-4ClPhe-Lys-Leu-ACC (CSL173, structure
in Figure 2A). With a kcat/KM value of 9.6 × 10
6 M−1 s−1, this
substrate was cleaved by Hip1 5000 times faster than was MarP
substrate WKLL-ACC (Table 1). Furthermore, the substitution
of optimal amino acids in either the P3 or P4 position with a
nonpreferred amino acid led to a decrease in the kcat/KM value
by 1−3 orders of magnitude. In addition, when P2-Lys was
replaced by Tyr, the catalytic efficiency dropped by over
10 000-fold, even though the other optimal amino acids in the
P1, P3, and P4 positions were retained, again highlighting the
dominant contribution of this residue to the overall substrate
specificity of the protease.
Given that macrophages are important hosts for Mtb, we
wanted to determine whether our newly identified selective
substrates could be used to monitor Hip1 activity in the
background of total extracts derived from a macrophage cell
line (RAW cells). We measured the cleavage of all four
substrates when added to RAW cell lysates (1 μg) that had
been spiked with a range of concentrations of recombinant
Hip1 (Figure 2C,D). We found that both optimal substrate
CSL173 and next-best substrate CSL174 (structure in Figure
2B) showed a clear increase in signal depending on the amount
of Hip1 present, with CSL173 showing a 10-fold signal over the
background when only 270 pg (0.027% of total protein) of
Hip1 was added. However, although the overall signals for
CSL173 were higher than for CSL174, there was some cleavage
in lysates that did not contain Hip1, suggesting that CSL173 is
likely less selective than CSL174. However, the overall strong
signal-to-noise ratio observed upon addition of small quantities
of Hip1 for both probes suggests that they have the potential to
be used to selectively monitor Hip1 activity in complex
biological settings.
In addition to substrate probes, we wanted to develop
inhibitors and ABPs that could be used to permanently label
and inactivate Hip1. One of the benefits of covalent ABPs
compared to substrates is that it is often easier to design highly
selective ABPs for a target by making use of electrophiles that
specifically react with subclasses of proteases (i.e., only serine
proteases). Therefore, we used our optimal substrate as a
starting point for covalent inhibitor design and attached the
serine protease-specific diphenyl phosphonate (DPP) electro-
phile that has proven to be effective for other serine protease
targets.14,15 Conversion of the CSL173 substrate into the
corresponding peptide DPP (compound 1, Figure 3A) resulted
in a compound that showed complete inhibition of the
recombinant Hip1 at low micromolar concentrations (Figure
3B). However, we found that this compound did not show a
time-dependent inhibition that would be expected for an
irreversible inhibitor, suggesting that it acts as a reversible
competitive inhibitor (Figure 3C). We reasoned that the bulky
phenyl groups attached to the electrophile may not fit
effectively in the Hip1 active site, preventing the phosphonate
from covalently reacting with the serine active-site nucleophile.
To identify potential irreversible pharmacophores for the
Hip1 ABP design, we screened Hip1 against a highly focused
library of ∼500 small molecules containing serine-reactive
electrophiles using the fluorogenic substrate assay as a readout.
We previously used this compound library to identify inhibitors
of other serine protease targets.16 The screen identified a series
of 7-amino-4-chloro-3-(2-bromoethoxy)isocoumarins as hits,
with the top compound 2 (JCP363, Figure 3D) inhibiting Hip1
with an IC50 of ∼120 nM (Figure 3E). Importantly, unlike the
DPP inhibitor, this compound showed time-dependent
inhibition, suggesting that it acts as a covalent irreversible
inhibitor (Figure 3F). We also identified a structurally related 4-
chloro-3-(2-bromoethoxy)isocoumarin (compound 3, Figure
3G) that was ∼17-fold less potent against Hip1 (Figure 3H)
Figure 2. Selective fluorogenic substrate probe to visualize Hip1
activity. (A) Structure of optimal fluorogenic Hip1 substrate acetyl-Igl-
(4Cl)Phe-Lys-Leu-ACC (CSL173) and (B) acetyl-Asp-(4Cl)Phe-Lys-
Leu-ACC (CSL174). (C) Rates of cleavage of fluorogenic substrates
WKLL-ACC, CSL173, CSL174, CSL175, and CSL176 (at 1 μM) in
RAW cell lysates (1 μg) with increasing amounts of recombinant Hip1
(0, 2.7, 27, or 270 pg) added. Data are plotted as the rate of change in
the signal over the linear portion of the progress curves. (D) Data
from B plotted as a function of the signal relative to the background
for each substrate.
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Figure 3. Validation of Hip1 inhibitors and activity-based probes. Hip1 activity was measured using the cleavage of fluorogenic substrate WKLL-
ACC. All curves show the mean ± S.D. of triplicates. (A) Chemical structure of 1, a DPP electrophile conjugated to the Igl-(4-Cl)Phe-Lys-Leu
specificity sequence identified by substrate profiling. (B) Dose−response curve for compound 1 when added to Hip1 without any preincubation. The
calculated IC50 value is shown. (C) Time-dependent effects of compound 1 on Hip1 activity. Hip1 (3 nM) and 1 (100 nM) were preincubated for
various time periods before the measurement of Hip1 activity. The values for mRFU/s are plotted for each preincubation time point. (D) Structure
of chloroisocoumarin-based screening hit 2. (E) Dose−response curves of 2 in a Hip1 activity assay. The curve for a 30 min preincubation (solid
line, IC50
30 min) is compared to when 2 was added simultaneously with substrate (dashed line, IC50
0 min). The calculated IC50 value is indicated. (F)
Time-dependent effects of compound 2 on Hip1 activity. Hip1 (3 nM) and 2 (100 nM) were preincubated for various time periods time before the
measurement of Hip1 activity. The values for mRFU/s are plotted for each preincubation time point. (G) Chemical structure of 3, an analog of 2
with ∼17-fold lower inhibitory activity. (H) Dose−response curve of 3 against Hip1 in a fluorogenic substrate assay. IC50 is shown. (I) SDS-PAGE
analysis of RAW cell lysates with or without recombinant Hip1 added were labeled with the fluorescent serine hydrolase probe FP-TMR after
preincubation with chloroisocoumarin 2, its inactive analog 3, DPP inhibitor 1, or general serine protease inhibitor AEBSF. The arrow indicates the
position of the labeled Hip1, and the open arrowheads indicate off-target enzymes hit by the compounds. (J) Chemical structure of 4, a fluorescent
activity-based probe analog of 2. (K) Dose−response curve of 4 in a Hip1 fluorogenic substrate assay. (L) SDS-PAGE analysis of RAW cell lysates
with or without added Hip1 labeled with 4. The arrow indicates the position of labeled Hip1.
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and could be used as a negative control analog for future
specificity studies.
To further assess the specificity of the newly identified lead
chloroisocoumarin (2), we tested its ability to bind to
recombinant Hip1 that had been added to RAW cell lysates
(Figure 3I). To measure the binding and overall selectivity, we
added the compound to the spiked lysate at various
concentrations and then labeled active Hip1 as well as other
RAW-cell-derived serine hydrolases using the general serine
hydrolase probe fluorophosphonate(FP)-TMR. We also
performed this competition analysis for the original DPP
inhibitor 1 and the inactive control compound 3. As expected,
we found that compound 2 blocked Hip1 labeling by FP-TMR
at both concentrations tested, whereas reversible compound 1
and control inactive compound 3 did not. However, we also
observed that compound 2 blocked the labeling of several other
prominent FP-TMR-labeled species (open arrowheads in
Figure 3I), suggesting that this compound is not very selective
for Hip1.
Given that our top hit was potent against Hip1 in the
nanomolar concentration range, we reasoned that it could be
converted to an ABP by the addition of a fluorescent tag. The
resulting fluorescent probe version of 2 (compound 4, Figure
3J) irreversibly inhibited Hip1 with a potency similar to that of
parent compound 2 (Figure 3K, (kobs/[I] ≈ 1012 ± 5 M−1
s−1)). However, when we used probe 4 at 1 μM to label RAW
lysates containing Hip1, it labeled several other proteins with
only weak labeling of the desired target (Figure 3L). This result
was consistent with the competition labeling studies suggesting
that while compound 2 is a potent inhibitor of recombinant
Hip1, it is not selective enough to be used as a probe in
complex biological samples containing significant off-targets.
These results are also consistent with the fact that compound 2
had previously been reported to be a potent inhibitor of the
serine protease human neutrophil elastase (HNE) with kobs/[I]
> 480 000 M−1 s−115 with additional weak activity against
chymotrypsin and cathepsin G.16 Therefore, we used HNE as
the most relevant off-target for testing the selectivity of
substrates and inhibitors. We found that the most effective
Hip1 substrate, CSL173, had a nearly 10 000-fold selectivity for
Hip1 over HNE (Table 1), and the next-best substrate CSL174,
which was only 40-fold less effective for Hip1 than was
Figure 4. Optimization of chloroisocoumarin-based inhibitors using substrate selectivity information. (A) Plot of the relative IC50 values for a series
of R1-7-amino-4-chloro-3-(2-bromoethoxy)isocoumarins as measured using the fluorogenic substrate assay. The plotted values represent the ratio of
IC50 for compound 2/IC50 for each indicated analog. (B) Chemical structure of optimized Hip1 inhibitor 5. (C) Second-order rate constants kobs/[I]
of compounds 2 and 5 calculated for Hip1 and HNE. (D) SDS-PAGE analysis of RAW cell lysates containing recombinant Hip1 that were labeled
with the fluorescent serine hydrolase probe FP-TMR after preincubation with optimized Hip1 inhibitor 5, screening hit 2, or inactive analog 3. The
black arrowhead shows the location of labeled Hip1, and gray arrowheads show the position of enzymes hit nonspecifically by compound 2.
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CSL173, was not cleaved by HNE at all. This data suggests that
the incorporation of binding determinants identified by Hip1
substrate profiling is likely to increase the potency and
selectivity of inhibitors and covalent probes toward Hip1.
Because the major determinant for selectivity to Hip1 was
the Lys in P2 (Figure 1B,E, Supporting Information Figure 2A),
we generated analogs of compound 2 containing various lysine
mimetics attached to the chloroisocoumarin scaffold (Figure
4A). Originally, the C3 substituents of the chloroisocoumarins
(such as the bromoethoxy group in 2) were thought to occupy
the S1 pocket of the target protease, implying that the C7
substituent would be directed toward the S′ sites.16 However, it
was later determined that the C3 substituent might be
positioned toward the S1′ sites depending on the protease
and inhibitor.17 We therefore reasoned that it might be possible
to address the S2 pocket with a substituent conjugated to the
C7 position of 2. To verify this hypothesis, we synthesized a
series of 7-R1-CONH-4-chloro-3-bromoethoxyisocoumarins
using Fmoc-protected amino acids in R1. Compound 5,
featuring Fmoc-L-Lys at R1 (Figure 4B), was the most potent
inhibitor in this series (IC50 of ∼34 nM, which is ∼4-fold
improved over parent compound 2, Figure 4A). R1 amino acids
with aliphatic side chains (Leu) or modified amines (L-Lys(N-
biotin)) were less potent than 2, whereas other substituents
with primary amines of different chain lengths or stereo-
chemistries (L-Orn, L-hLys, D-Lys) were better inhibitors than
2 but less potent than 5. Importantly, we also observed an
overall increase in the specificity of compound 5 for Hip1 over
HNE compared to that for compound 2. Specifically,
compound 5 inactivated Hip1 15-fold faster than compound
2 yet was an ∼8-fold-weaker inhibitor than compound 2 for
HNE. To further demonstrate this enhanced specificity of
compound 5, we again used competitive activity-based protein
profiling using FP-TMR in murine macrophage lysates
containing recombinant Hip1 (Figure 4E). Importantly, we
found that newly designed compound 5 showed the highly
selective inhibition of Hip1 labeling with markedly reduced or
virtually no activity toward the many other hydrolases that were
effectively targeted by compound 2. Overall, these results
confirmed that the use of our substrate specificity data to
further optimize our screening hit resulted in a compound of
greatly improved potency and selectivity for Hip1.
Because our long-term goal is to develop probes to visualize
Hip1 activity in vivo, we proceeded to test whether the
substrates can be used to monitor Hip1 activity in live bacteria.
This would also allow us to determine if the peptide substrates
could access the enzyme in live cells. Importantly, we observed
that both of the optimized Hip1 substrates, CSL173 and
CSL174, were readily processed by WT Mtb (CDC1551) but
not by a previously described Hip1-KO strain9a (Figure 5A). In
contrast, the control substrate for trypsin-like proteases (Z-
GGR-AMC) was processed only weakly and at a similar rate by
both strains, and control substrate CSL176 was processed by
neither strain (Figure 5A). These results indicate that
processing CSL173 and CSL174 by Mtb is dependent on
Hip1 and that these probes readily penetrate the bacterial cell
envelope where Hip1 is located. These fluorogenic substrates
enabled us to determine if our optimized inhibitor 5 blocked
Hip1 activity in intact bacterial cells. Using this assay, we found
that compound 5 blocked Hip1 activity in a dose-dependent
manner as measured by a block in the CSL174 signal (Figure
5B). These results confirmed that 5 inhibits endogenous Hip1
in its physiological environment. The relatively high concen-
trations required to get effective inhibition of Hip1 activity may
be due to the low permeability of the inhibitor to the
mycobacterial cell wall and/or may be the result of the limited
incubation time (1 h) used in this assay.
As a final step of validation, we wanted to confirm that our
substrate probes produce a Hip1- and Mtb-specific signal in
Mtb-infected J774.1 murine macrophages. Our results con-
firmed that both CSL173 and CSL174 produced a specific
signal in macrophages infected with WT Mtb, but not in
macrophages infected with Hip1-KO Mtb. Interestingly, we
observed the largest signal over background signals for CSL174
as this probe showed virtually no activity in the macrophages
infected with Mtb lacking Hip1. These data are in agreement
with our in vitro results using Hip1 spiked into macrophage
lysates (Figure 2), where we found that CSL174 had overall
lower signals in macrophage extracts than did CSL173. Thus,
CSL174 is an ideal candidate for translation into an Mtb-
specific quenched fluorescent substrate for noninvasive optical
in vivo imaging of tuberculosis.
We believe that we have identified a valuable new reagent for
use as a probe as well as a new inhibitor of Mtb protease Hip1.
However, we recognize that additional medicinal chemistry
efforts may be required to further enhance the selectivity and
potency of the chloroisocumarin inhibitor to avoid targeting
other host-derived proteases such as HNE. For example,
modifications at the C3 position, replacing the bromoethoxy
group that drives the potency for HNE,16 might allow us to
address the prime or nonprime sites of Hip1 from this position.
Furthermore, both the C3 position and the peptide moiety at
Figure 5. Validation of fluorogenic Hip1 substrates and inhibitors in live M. tuberculosis. (A) Proteolytic processing of CSL173, CSL174, and
CSL176 and the control fluorogenic substrate Z-GGR-AMC (each at 1 μM) by live WT Mtb or Hip1-KO Mtb. Data is shown as relative
fluorescence units after 30 min of incubation normalized to the background autofluorescence. (B) Proteolytic processing of the indicated fluorogenic
substrates in WT Mtb after preincubation with Hip1-specific inhibitor 5 or general serine hydrolase inhibitor AEBSF at the indicated concentrations
for 1 h prior to addition of substrates. (C) Fluorogenic substrate cleavage by J774.1 murine macrophages infected with either WT Mtb or Hip-1 KO
Mtb (MOI = 10) for 3 h. Extracellular bacteria were washed away before substrates were added. Data is displayed as relative fluorescence units after
90 min of incubation normalized to the autofluorescence background. All graphs show mean ± SD values of triplicates.
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C7 may be suitable anchor points for the attachment of tags,
such as fluorophores, biotin, or a click-chemistry handle to
make Hip1-selective ABPs. Whether such ABPs will readily
penetrate the bacterial cell wall to reach their target will be the
subject of future studies. However, the Hip1-reporter substrates
presented in this work provide a target-specific readout for a
cell-based assay that may be used for high-throughput screening
of large compound libraries to identify new classes of cell-
permeable Hip1 inhibitors. Importantly, these Hip1-selective
reporter substrates may already be useful for visualizing Hip1
activity in relevant biological samples or even clinical samples.
These initial probes can easily be translated into quenched
fluorescent substrates for further applications such as non-
invasive in vivo imaging, as has been established for the cysteine
cathepsins.7
In conclusion, the combination of substrate profiling and
focused compound screening in the design of selective chemical
probes as demonstrated here for Hip1 should prove valuable for
many proteases of interest. A recent chemoproteomics study
identified 78 putative Mtb serine hydrolases under replicating
and nonreplicating growth conditions.8 However, with the
notable exception of inhibitors for Mtb caseinolytic protease
clpP1P2,18 there are no selective inhibitors or ABPs for any of
these targets. Because many of these serine hydrolases have not
been functionally characterized,8 they are currently not
accessible to target-based probe design using purified
recombinant enzymes. In ongoing work in our laboratory to
overcome this limitation, we are establishing a competitive
activity-based protein profiling approach that would allow the
direct screening of focused libraries to discover candidate
inhibitors and probes for unidentified serine hydrolases in
complex mycobacterial lysates. The resulting lead compounds
may be useful both for the study of protease function and to
generate probes that can be used for target enrichment
followed by mass spectrometry-based identification. Once
identified, proteases can be expressed and then subjected to
the target-based probe design approach presented in this study.
We believe such strategies will be required to build a chemical
toolbox with reagents for mycobacterial proteases that have
potential value for next-generation target validation, drug
development, and diagnostic monitoring efforts.
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